1

CMIRPS
Canadian Medication Incident Reporting and Prevention System
Is a collaborative pan-Canadian program of Health Canada, the Canadian Institute for Health Information
(CIHI), the Institute for Safe Medication Practices Canada (ISMP) and the Canadian Patient Safety Institute
(CPSI). The goal of CMIRPS is to reduce and prevent harmful medication incidents in Canada.

CIHI
Canadian Institute of Health Information
A web tool for the health sector and general public. It provides comparable, interactive data so that
hospitals, regions, provinces and territories can compare how they measure up on 37 indicators related to
access, quality of care, patient safety & emerging health trends across the country. CIHI produces analytic
reports from NSIR data and makes it publicly available.

NSIR (software)
National System for Incident Reporting
Is a web-based application to securely and anonymously share, analyze and discuss medication incidents &
operated by Canadian Institute of Health Information (CIHI)

ISMP
Institute for Safe Medication Practices Canada
It is an independent national organization committed to the advancement of medication safety. It works
with the healthcare community to promote safe medication practices & making recommendations for the
prevention of harmful medication incidents.

CPhIR
The Community Pharmacy Incident Reporting (Designed by ISMP Canada, announced 12 September 2014)
This program provides community-based pharmacies with a secure, one-stop, online location to
anonymously report and analyze medication incidents; export data for customized analysis; and view
comparisons of individual pharmacy and national aggregate data.

CPSI
Canadian Patient Safety Institute
Works with governments, health organizations, leaders, and healthcare providers to raise awareness and
facilitate implementation of ideas and best practices to achieve a transformation in patient safety. They
envision safe healthcare for all Canadians and are driven to inspire extraordinary improvement in patient
safety and quality.

Canada Vigilance Program (MedEffect™)

Post-market surveillance program that collects and assesses reports of suspected adverse drug reactions
marketed in Canada. Adverse drug reaction reports should be submitted to the Canada Vigilance Program that
operated by Health Canada.
 2

DPD
Drug Product Database
A database contains product specific information on drugs approved for use in Canada. The database is
managed by Health Canada and includes human pharmaceutical and biological drugs, veterinary drugs
and disinfectant products.
CHA
Canada Health Act
A federal legislation that puts in place conditions by which provinces & territories in Canada may receive
funding for health care services
There are 5 main principles in the Canada Health Act (PUPAC)
 Public Administration
 Universality
 Portability
 Accessibility
 Comprehensiveness
(All EXCEPT Affordability)

CADTH
Canadian Agency for Drugs and Technologies in Health
Independent, non-profit, funded by Federal, Provincial and Territorial.
Provides decision-makers with the evidence, analysis and advice about the effectiveness of drug and devices, and
recommendations they require to make decisions (approval) of drug registration in health care.

CADTH has 3 programs

1-HTA Health Technology Assessment
Assessment of drug, health technology.

2-CDR Common Drug Review

A conducting reviews of the clinical, cost-effectiveness, and patient evidence for drugs and providing
formulary listing recommendation.

3- COMPUS Canadian Optimal Medicine Prescribing and Utilization Services.

Identify and promoting the optimal drug use through pharmacists (Academic Detailing or Pharmacist
Physician Detailing or Counter Detailing) → Canadian Academic Detailing Collaboration (CADC) →
improvements observed in physician prescribing of: Ab, BDZs, and NSAIDs

NOC
Notice of Compliance
Is issued to a manufacturer following the satisfactory review of a submission for a new drug, and signifies
compliance with the Food & Drug Regulations, it allow the drug to be released to market.

PIPEDA
Personal Information Protection and Electronic Documents Act
Support and promote electronic commerce by protecting personal information that is collected, used or
disclosed in certain circumstances.
 3

PHIPA
Personal Health Information Protection Act
Assure confidentiality of patients’ information.

RHPA
Registered Health Professional Act
Do not date patients, from your pharmacy and fill their Rx (even your spouse)

HPB
Health Protection Branch
Responsible for Drug Quality, Safety and Efficacy
Imported and Manufactured drugs sale in Canada

MHPD
Marketed Health Products Directorate
Monitors the safety, effectiveness, and quality of marketed health products in Canada

HPFB
Health Products & Food Branch.
Responsible for Post-market surveillance of marketed health products
Sub-branches are SAP & TPD

SAP
The Special Access Programme
Provides access to non-marketed drugs for practitioners treating patients with serious or life-threatening
conditions when conventional therapies have failed, are unsuitable, or unavailable (a quantity of 6 months
or less)

TPD
Therapeutic Products Directorate
Federal authority that regulates Rx, Non-Rx products and medical devices for human use in Canada.

NPHD
Natural Health Products Directorate
 Regulates natural health products, vitamins / mineral supplements & herbal products.
 Assign NPN for each natural product approved for market.

PMPRB
Patented Medicines Prices Review Board
Control price of brand (not generics)
 4

DSMB
Data Safety Monitoring Board
 Reviews data while clinical trial is in progress
 May recommend that a trial stopped for safety concerns.